Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS. Bile acids are cholesterol metabolites that can signal through receptors on cells throughout the body, including the CNS and immune system. Whether bile acid metabolism is abnormal in MS is unknown.
expected, RRMS patients were younger and PMS patients were older than the healthy controls (Supplementary Table 2 Secondary bile acid metabolism pathway deregulation scores (adjusted for age, sex, and race) were higher for both MS groups compared to controls (Figure 1d ).
To extend our initial observations, we performed targeted metabolomic profiling of 15 bile acids (Supplementary Table 3 ) in plasma from a larger cohort of MS patients (RRMS: n=50, PMS: n=125) and controls (n=75). Again, the PMS patients were older than RRMS patients and healthy controls (Supplementary Table 2 Comparison of between-group pathway deregulation (adjusting for age, sex, and race) revealed significantly higher scores (denoting greater abnormality) for both primary and secondary bile acid metabolism in the PMS group compared to controls (Figure 1f and g ).
To model metabolism of bile acids in the gut, we studied the ratio of secondary bile acid metabolites to their primary bile acid precursors, since secondary bile acid production requires multiple reactions catalyzed by enzymes present in the gut microbiota 4, 19 . We noted a significant increase in the ratio of deoxycholic acid (DCA) metabolites (DCA, GDCA, TDCA) to cholic acid (CA) metabolites (CA, GCA, TCA) in the PMS group with a trend towards a higher ratio in the RRMS group ( Figure 1h ). Individual ratios of DCA to either glycine or taurine-conjugated forms of CA were also elevated in the PMS (Figure 1i and j) but not the RRMS group. In the alternative bile acid synthesis pathway, a similar change was seen with an increased ratio of the lithocholic acid (LCA) and ursodeoxycholic acid (UDCA) metabolites to chenodeoxycholic acid (CDCA) metabolites in the PMS but not the RRMS group compared to controls ( Figure 1k ).
Overall, the data from both metabolomics approaches in the adult cohorts revealed alterations in bile acid metabolism in patients with MS, with greater abnormality noted in the PMS group.
Bile acid metabolism is altered in pediatric-onset multiple sclerosis
We then performed global metabolomic profiling in a cohort of pediatric-onset MS patients (n=31) and age-, race-and sex-matched controls (n=31) drawn from the UCSF Pediatric MS Center (Supplementary Table 4 ). Lower levels of several primary and secondary bile acid metabolites were seen in the pediatric MS patients compared to controls (Fig 2a-c, Supplementary Figure 2) . Several of the metabolites that were differentially altered between groups overlapped with the adult cohorts. Comparison of pathway deregulation scores for primary bile acid metabolism revealed greater abnormality in the pediatric MS group compared to controls ( Figure 2d ). A significant increase in the ratio of DCA to CA metabolites was found, similar to that seen in adult MS patients (Figure 2f ). These results demonstrate that in a cohort of pediatric-onset MS patients derived from an independent site, we identified bile acid metabolism abnormalities similar to those noted in adult MS patients.
Bile acid receptors are expressed in white matter lesions from MS patients
After establishing altered bile acid metabolism in both adult and pediatric MS patients, we We polarized murine microglia to a pro-inflammatory phenotype by treating with IFN-γ and LPS, with or without TUDCA present. We noted a reduction in the expression of NOS2 gene ( Figure 4e ) -a marker for M1 polarization and reduction in IL1A and TNFA transcription in the presence of TUDCA (Figure 4f and g ). Thus, TUDCA, an endogenous bile acid, blocked the in vitro polarization of astrocytes to an A1 toxic phenotype and the polarization of microglia to a pro-inflammatory M1 phenotype.
TUDCA supplementation ameliorates experimental autoimmune encephalomyelitis (EAE)
Since multiple circulating bile acid levels were lower in MS compared to healthy controls and TUDCA prevented the proinflammatory polarization of microglia and astrocytes, we next tested the effect of TUDCA supplementation in an animal model of MS -experimental autoimmune encephalomyelitis (EAE). EAE was induced by active immunization with MOG peptide and mice were randomized to receive either TUDCA 500 mg/kg orally or vehicle when they reached a disease severity score of 1 ( Figure 5a ). We noted reduction in the severity of EAE based on Figure 4) . We evaluated the presence of pro-inflammatory (M1) microglia/ macrophages using staining for iNOS and Iba-1 and noted a reduction in the proportion of iNOS+ Iba-1+ cells (Figure 5i and j).
We also evaluated A1 astrocytes in EAE spinal cord tissue using staining for PSMB8 and GFAP, since PSMB8 was previously noted to be a marker of neurotoxic (A1) astrocytes 21 . A reduction in PSMB8+ GFAP+ cells was seen with TUDCA treatment (Figure 5k and l) suggesting a reduction in A1 astrocytes. These data are consistent with the in vitro data regarding the effects of TUDCA on both microglial and astrocytic polarization. Since CD4+ T cells are key players in the pathogenesis of the EAE model we tested the effects of TUDCA on CD4+ T cell proliferation and cytokine production in vitro and noted no direct anti-inflammatory effects of TUDCA on CD4+ T cells, as assessed by these measures (Supplementary Figure 5) . These data suggest that TUDCA supplementation ameliorates neuroinflammation through reduced infiltration of immune cells and decreased microgliosis and astrocytosis.
Discussion
In this study, we demonstrate that bile acid metabolism is altered in both adult and pediatric- . Cues from microglia influence astrocytic phenotype and impact neuroinflammation 21, 22 . We confirmed that TUDCA not only prevented pro-inflammatory polarization of microglia, but also reduced production of factors implicated in the polarization of astrocytes to an A1 phenotype. Besides the potential indirect effect through prevention of microglial polarization, we identified that TUDCA can act directly on astrocytes and block A1 polarization. TUDCA treatment decreased upregulation of A1-specific genes and the change in gene expression resulted in a functional change -reduced toxicity of ACM to oligodendrocytes.
To the best of our knowledge, this is the first example of an endogenous metabolite that directly blocks the polarization of astrocytes to a toxic phenotype. This has important implications since this subset of astrocytes could play a critical role in neurodegeneration in disorders such as
Parkinson's disease (PD), AD and MS 21 . Since, we noted that astrocytes in both humans and mice express the GPBAR1 receptor, we tested whether the effects of TUDCA on astrocyte polarization could be replicated using a GPBAR1 agonist -INT777. We identified partial replication of the effects of TUDCA with INT777 suggesting that this beneficial effect may be partially mediated through GPBAR1. A previous study has also reported that the GPBAR1 receptor may mediate anti-inflammatory effects of TUDCA on microglial cells 16 . Thus, while our data suggests that GPBAR1 may be important for the effects of bile acids on astrocyte polarization, the precise mechanism requires further study.
The identification of altered serum levels of bile acids in MS is not entirely unexpected given that gut dysbiosis has been reported in MS patients in several studies 9, [23] [24] [25] . Since modification of bile acids by the gut microbiota is a key step in their metabolism, the alteration in abundance of bacterial species that are involved in these processes could potentially explain altered circulating levels of bile acid metabolites in MS. Indeed, bacterial species including Clostridium and Parabacteroides which have been noted to be reduced in abundance in MS are important players in bile acid metabolism and have been linked to alteration in circulating levels of certain bile acids 10, 19, 26 . The change in ratios of secondary to primary bile acids in both synthesis pathways also points to the potential role of gut dysbiosis as a key factor driving this change. The observation that these changes was more marked in progressive MS parallels the trend noted in AD, where the change in bile acid profiles was more marked in AD than in mild cognitive impairment (MCI) 4 . This potentially suggests a relationship between greater abnormality in bile acid metabolism and neurodegeneration.
As the makeup of the gut microbiota is linked to an individual's genome, circulating metabolite levels could also be driven by specific genetic factors 26 . In a recent study, vitamin D receptor (VDR) polymorphisms were demonstrated to alter Parabacteroides abundance and ultimately impact the level of specific bile acids 26 . Similarly, other MS-related genetic risk alleles could alter the gut microbiota and ultimately lead to metabolic changes such as those noted in our study. For example, ZFP36L1 (a gene identified in several MS GWAS studies) was recently demonstrated to modulate bile acid biosynthesis 27 .
Besides altered gut microbial bile acid metabolism, altered bile acid profiles could result from abnormal endogenous production. Since cholesterol is the precursor of bile acids, alterations in cholesterol metabolism could potentially underlie changes in bile acid abundance. Cholesterol metabolism is intricately linked to T cell and innate immune cell function 28 . Inflammation can alter cholesterol metabolism in the CNS and this was the major abnormal pathway in a recent study evaluating spinal cord astrocyte gene expression profiles in EAE 11 . These data suggest that inflammation can alter endogenous cholesterol metabolism, in the CNS and the periphery and could be a factor underlying the altered bile acid levels in MS patient circulation.
We examined the distribution of two key bile acid receptors in MS brains. FXR is a nuclear bile acid receptor present in MS white matter lesions from RRMS patients -primarily in immune cells 29 . We found that in addition to active lesions, FXR expression can also be found in chronic MS lesions. We also identified the presence of GPBAR1 on astrocytes and vascular structures in MS lesions. The expression of GPBAR1 on astrocytes raises the possibility that the circulating bile acid metabolites could potentially alter neuroinflammation through effects on these cells. In animal models, GPBAR1 expressed on the endothelium helped regulate chemotaxis of immune Previous studies have demonstrated that bile acid levels are reduced in chronic EAE, providing a strong rationale for testing bile acid supplementation in this animal model 12 . This provides in vivo corroboration of the anti-inflammatory effects of bile acid supplementation that we noted initially in our in vitro experiments. The primary mechanism of the beneficial effects of bile acid supplementation in the EAE model -whether related to GPBAR1 activation in glial cells or FXR activation in peripheral myeloid cells requires further study.
Our study has several strengths. We demonstrated abnormal bile acid metabolism in two cohorts from different centers and in different age groups. Besides evaluating this observation in humans, we also evaluated the effects of bile acids in vitro and in an animal model of MS. The limitations of the current study include the cross-sectional nature of the metabolomics analyses precluding an assessment of how bile acids change over time in MS and whether they are affected by specific MS disease-modifying therapies. Fewer bile acid metabolites were measured in the targeted cohort compared to the untargeted panel, i.e. not all metabolites were present in both data sets for direct comparison. However, we did note that the majority of metabolites 13 demonstrated consistent changes across all the cohorts. Finally, human samples were obtained after disease onset which precludes evaluation of causality.
Future studies will help further define the relationship between bile acid levels and MS disease course. Additionally, ongoing clinical trials of supplementation with TUDCA in MS (NCT03423121) are likely to provide us with information regarding the effects of this intervention on circulating bile acid levels and ultimately on MS activity and disease course.
The results of this study expand our understanding of how alterations in the metabolome may affect aspects of MS disease pathophysiology and potentially impact processes that mediate neurodegeneration in multiple neurological diseases. We also provide a paradigm for future studies to identify additional metabolic pathways that could be targeted to modify the course of MS.
Methods

Patient cohorts
We recruited adult MS patients and healthy controls from the Johns Hopkins MS Center.
Participants underwent phlebotomy for blood collection in addition to collection of clinical and demographic data. Blood was processed using our standard protocol and plasma stored at -80 C until the time of metabolomics analyses. We had two adult cohorts in this study -a discovery cohort consisting of 56 RRMS, 51 PMS and 52 HC that underwent global metabolomics analysis and a validation cohort which consisted of 75 HC, 50 RRMS and 125 PMS that underwent targeted metabolomics analysis. Pediatric MS patients and healthy controls (n=31 each) were recruited from the UCSF Pediatric MS clinic. Participants underwent phlebotomy and blood was processed and serum stored at -80 C until the time of metabolomics analyses 32 .
Global Metabolomics analyses
Global metabolomics analyses were performed at Metabolon Inc (Durham, NC) as previously described 33 . In brief, recovery standards were added prior to the extraction process for quality control. To remove protein and to recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking (Glen Mills Genogrinder 2000) for 2 minutes, followed by centrifugation. The resulting extract was divided into 5 fractions: analysis by ultrahigh-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS; positive ionization), UPLC-MS/MS (negative ionization), UPLC-MS/MS polar platform (negative ionization), gas chromatography-mass spectrometry, and one aliquot was reserved for backup.
Metabolite identification was performed by automated comparison of the ion features in the study samples to a reference library of standard metabolites. Quantification of peaks was performed using area under the curve. Raw values for the area counts, for each metabolite were normalized (correcting for variation resulting from instrument inter-day tuning differences) by the median value for each run day.
Targeted metabolomics assay
The targeted bile acid panel measured all of the major human primary and secondary bile acids or product ion. Quantitation was performed using a weighted linear least squares regression analysis generated from fortified calibration standards prepared immediately prior to each run.
Single level pooled QC samples were used with most bile acid concentrations at the endogenous level. Due to low abundance of TUDCA, TCA, TLCA, GLCA, and LCA in this lot, the QCs were up-spiked to typically observed levels (standard C to D range). Due to multiplexing 15
analytes, only a single concentration level of QC samples was used. Raw data were collected and processed using AB SCIEX software Analyst 1.6.3. Data reduction was performed using Microsoft Excel 2013.
Sample analysis was carried out in the 96-well plate format containing two calibration curves and six QC samples (per plate) to monitor method performance. Four sample batches were prepared and analyzed. Following analysis, four samples were found to be above the limit of quantitation (ALOQ) and therefore re-analyzed at a 5-fold dilution. Precision was evaluated using the corresponding QC replicates in each sample run. Intra-run and inter-run precision (%CV) of all analytes met acceptance criteria.
Immunohistochemistry of MS autopsy tissue
All brains were collected as part of the tissue procurement program approved by the Cleveland Clinic Institutional Review Board. Multiple sclerosis (MS) brain tissues were characterized for demyelination by immunostaining using 30 µm fixed tissue sections and proteolipid protein (PLP) using protocols described previously [34] [35] [36] . Briefly, fixed blocks of the tissue were cut on a sliding microtome, microwaved in 10 mM citric acid buffer (pH 6.0) and immunostained by the avidin-biotin complex procedure with diaminobenzidine (DAB) using rat anti-proteolipid protein Invitrogen, Carlsbad, CA). Immunofluorescent-labeled tissues were analyzed using a Leica DM5500 upright microscope (Leica Microsystems, Exton, PA). PLP-TGR5 and GFAP-TGR5 images were collected from corresponding sections. Resultant images were processed using Fiji version (http://fiji.sc) of the free image processing software ImageJ (NIH, http://rsbweb.nih. gov/ij) as described before [34] [35] [36] .
Murine Microglia Primary Cultures
Microglia were isolated from brains of post-natal day 3 -5 mouse pups. After dissecting off the meninges, whole brains underwent mechanical and enzymatic dissociation using Neural Tissue 
Murine Astrocyte Primary Cultures
Astrocytes were isolated from brains of post-natal day 3 -5 mouse pups. Brains were enzymatically dissociated similarly to microglia (see above). Cells were Fc blocked with anti-CD16/CD32 antibodies then positively selected using ACSA-2 magnetic beads (Miltenyi, Bergisch Gladbach, Germany) and seeded onto poly-L-lysine-coated, 6-well plates at a density of 2.5 × 10 5 cells/mL. Astrocytes were cultured in serum-free media containing 50% DMEM, 50% neurobasal, 1% penicillin/streptomycin, 1% glutamax, 1 mM sodium pyruvate, N-acetyl cysteine (5 μ g/mL), 1 × SATO, and supplemented with HB-EGF (5 ng/mL, PeproTech, Rocky
Hill, NJ), as previously described 
Cell Viability Assay
Cells were seeded onto 96-well plates (50,000 microglia or astrocyte/well) and grown for 7 days well plates in oligodendrocyte base media (high glucose DMEM, 100U/ml penicillin, 100μg/ml streptomycin, 1mM sodium pyruvate, 4mM L-glutamine, 5ug/ml N-acetyl cysteine, 1x SATO, 1x B27, 5μg/ml insulin, 10ng/ml d-biotin, 1x trace elements B, 4.2μg/ml forskolin)
supplemented with 20ng/ml PDGFAA (Peprotech, Rocky Hill, NJ). Oligodendrocyte progenitors were allowed to proliferate and recover for several days and media was replaced with differentiation media-oligodendrocyte base media with 40ng/ml T3. After 24 hours of differentiation, 50μg/ml of concentrated astrocyte conditioned media was added to differentiated oligodendrocytes with Cytotox green (IncuCyte, Ann Arbor, MI) and NucLight rapid red (IncuCyte, Ann Arbor, MI). Plates were monitored in IncuCyte S3 Live-Cell Analysis system incubator and 10x images were captured. IncuCyte S3 program was used to set fixed threshold masks to quantify Cytotox and rapid red nuclear labeling. Images that met defined density thresholds of 5-50% on phase contrast and 1-25% on rapid red nuclear labelling were quantified.
Five experimental replicate sets of astrocyte conditioned media (A0, A1 and A1+ TUDCA 70μM treated) with 3-4 wells per replicate were quantified. Data was analyzed in GraphPad Prism 8.
For each well 3-14 images were quantified to calculate the mean and SEM of ratio of cytotox confluence/rapid red confluence per well. The mean of A0 cell death ratio was set to baseline of 1 and A1 and A1 + TUDCA 70μM conditions were compared to A0 baseline. Two-way ANOVA was used to compare means between well replicates and experimental samples.
Unpaired Welch's t test was used to compare two sample group means.
Experimental Autoimmune Encephalomyelitis induction and treatment
C57/BL6J mice were purchased from Jackson Laboratories. All mice were maintained in a federally approved animal facility at Johns Hopkins University in accordance with Institutional Animal Care and Use Committee. Female mice of 7-8 weeks of age were used in these experiments.
EAE was induced by s.c injection over two sites in the flank with 100 µg myelin oligodendrocyte glycoprotein (MOG 
Immunohistochemistry of EAE tissue
EAE mice were deeply anesthetized, then perfused transcardially with chilled PBS followed by 4% PFA. Spinal columns were dissected and post-fixed in 4% PFA overnight followed by cryoprotection with 30% sucrose for 48 hours. The spinal cords were then dissected and embedded in OCT before freezing. Tissues were sectioned on a cryostat (10 um sections) and mounted on glass slides (Super-frost Plus; Fisher, Hampton, NH). Blocking and permeabilization of sections was performed in PBS containing 5% normal goat serum (NGS) and 0.4% Triton X-100 for 1 h at room temperature followed by incubation overnight at 4°C in PBS containing 3% normal goat serum, 0.1% Triton X-100, and primary antibody (Supplementary Table 8 . We performed three independent experiments with a total of five biological replicates. All kits and reagents were used following manufacturers recommended protocols.
Statistical Analysis
For untargeted and targeted metabolomics data we excluded any metabolites that had greater than 30% missing values and then normalized and scaled the metabolite relative abundance. The pre-processed data was then used to generate pathway deregulation scores with the Pathifier package in R
37
. The pathway deregulation scores indicate the distance of an individual from a principal components curve generated using data from control subjects. The scores range from 0 to 1 with higher scores indicating greater abnormality.
The individual metabolite abundances and the pathway deregulation scores were then compared between groups using multivariate linear regression models adjusting for age, sex and race. We also generated heatmaps of Z-scores of the relative abundances of each of the bile acid The p values for a-e are derived from multivariate linear regression models adjusting for age, sex, and race. In f error bars represent standard error of the mean and p value is derived from a two-tailed unpaired Student's t-test. (a) Astrocytes were isolated from neonatal mouse brains using ACSA2-bead selection and were polarized to an inflammatory phenotype using a cocktail of IL 1α, TNF-α and C1q for 24 hours either in the presence or absence of TUDCA or INT-777 (GPBAR1 agonist). Quantitative PCR of genes associated with various astrocyte phenotypes revealed that expression of multiple A1-specific genes was significantly down-regulated in the TUDCA 70µM condition compared to vehicle. We also noted down-regulation of several A1-specific genes with INT-777 treatment but to a lesser degree than TUDCA 70µM. Data are derived from three independent experiments with six biological replicates. Groups were compared with Kruskal-Wallis test with Dunn's multiple comparisons test and asterisks represent p<0.05. (b) We concentrated astrocyte conditioned media from A0 (non-polarized), A1+ vehicle and A1+TUDCA 70µM conditions and tested the effects on viability of murine oligodendrocytes over a 24-hour period. (c) We noted reduced oligodendrocyte cell death with TUDCA 70µM ACM compared to vehicle (normalized to cell death from A0 ACM). Data is derived from three independent biological replicates and groups were compared with an unpaired two-tailed Student's t test. (d) Representative images depicting oligodendrocyte death testing ACM from the two conditions display greater cell death (Green) in vehicle condition compared to TUDCA 70µM. (e) Microglia were isolated from neonatal mouse brains using CD11b-bead selection and polarized to an inflammatory M1 phenotype by treatment with LPS and IFN-γ, either in the presence or absence of differing doses of TUDCA. We then isolated RNA to determine the expression of NOS2 gene, which is a marker of M1 polarization and noted reduced expression in TUDCA treated conditions compared to vehicle. We also compared gene expression for IL1A (f) and TNFA (g), which are factors produced by microglia critical for A1 polarization, in the various treatment conditions. We noted a significant reduction in gene expression for IL1A and a similar trend for TNFA in the TUDCA 70µM condition compared to vehicle. Data are derived from four independent experiments. We compared the groups with a one-way ANOVA with Dunnett's test for multiple comparisons. In c and e-g bars represent mean with error bars represent s.e.m. (* p<0.05, ** p<0.01, *** p<0.005, **** p<0.001). and CFA in addition to intraperitoneal injection of PTX on day 0 and day 2. We then monitored these mice for signs of EAE and at disease onset we randomized mice to oral gavage with either TUDCA 500 mg/kg or vehicle till day 28 post-immunization. 
